HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Watanabe, S. Articles by Gejyo, F. Search for Related Content PubMed PubMed Citation Articles by Watanabe, S. Articles by Gejyo, F. Pubmed/NCBI databases Medline Plus Health Information Skin Cancer

The Duration of Signaling through CD40 Directs Biological Ability of Dendritic Cells to Induce Antitumor Immunity

Department of Homeostatic Regulation and Development, Division of Respiratory Medicine, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan

Although it has been demonstrated that the functions of dendritic cells (DCs), including Ag capture, Ag presentation, and migratory activity, change dynamically with their maturation, the most appropriate conditioning of DCs for anticancer immunotherapy is still unclear. The help signal is one of the most potent stimuli for DC maturation and is provided by the interaction of CD40 expressed on DCs with CD40 ligand on CD4⁺ T cells. To elucidate the appropriate conditioning of DCs for anticancer immunotherapy, we examined the biological activity of DCs stimulated with immobilized anti-CD40 Ab. DCs stimulated for 3 h (3h-DCs) still showed an immature phenotype, but exhibited augmented migration toward secondary lymphoid tissues. Subcutaneous injection of 3h-DCs facilitated priming of T cells, which could mediate potent antitumor therapeutic efficacy, in draining lymph nodes and successfully induced protective immunity. In contrast, 24h-DCs showed a mature phenotype with good Ag presentation ability to induce cell killing by adoptively transferred CD8⁺ T cells when injected at tumor sites; however, they showed no migratory activity and were unable to induce protective immunity when injected s.c.. This is the first report that functionally distinct DCs, either for the priming phase or for the effector phase, could be obtained by conditioning with CD40 stimulation and that the duration of stimulation determines the biological outcome. The usage of DCs conditioned for the priming phase might provide significant advantages in anticancer immunotherapy.

This article has been cited by other articles:

				H. Wei, H. Wang, B. Lu, B. Li, S. Hou, W. Qian, K. Fan, J. Dai, J. Zhao, and Y. Guo Cancer Immunotherapy Using In vitro Genetically Modified Targeted Dendritic Cells Cancer Res., May 15, 2008; 68(10): 3854 - 3862. [Abstract] [Full Text] [PDF]

				E. Kim, S. H. Kim, S. Kim, D. Cho, and T. S. Kim AIMP1/p43 Protein Induces the Maturation of Bone Marrow-Derived Dendritic Cells with T Helper Type 1-Polarizing Ability J. Immunol., March 1, 2008; 180(5): 2894 - 2902. [Abstract] [Full Text] [PDF]

				T. Hiura, H. Kagamu, S. Miura, A. Ishida, H. Tanaka, J. Tanaka, F. Gejyo, and H. Yoshizawa Both Regulatory T Cells and Antitumor Effector T Cells Are Primed in the Same Draining Lymph Nodes during Tumor Progression J. Immunol., October 15, 2005; 175(8): 5058 - 5066. [Abstract] [Full Text] [PDF]

				M. Bellone, A. Camporeale, and A. Boni Dendritic Cell Activation Kinetics and Cancer Immunotherapy J. Immunol., March 1, 2004; 172(5): 2727 - 2728. [Full Text] [PDF]